Lucid Diagnostics Inc. (LUCD)
After hours:
| Previous close | 0.7230 |
| Open | 0.7300 |
| Bid | 0.6653 x 100 |
| Ask | 0.7070 x 100 |
| Day's range | 0.6750 - 0.7300 |
| 52-week range | 0.6750 - 1.8500 |
| Volume | |
| Avg. volume | 170,654 |
| Market cap | 32.956M |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings date | 26 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.83 |
PR NewswireLucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.
Insider MonkeyPAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript March 27, 2024 PAVmed Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to PAVmed’s Fourth Quarter and Full Year 2023 Business Update Conference Call. [Operator Instructions] This […]
